|
|
|
|
|
|
|
M T Wed Th F |
|
24 June, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
The recent biotech spending spree has done wonders for the C-suite psyche, our Endpoints 100 top executive survey shows. Read and watch (tomorrow at noon ET) John Carroll’s take on the most recent survey — and what the data reveal about CEOs’ current worries. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
 |
|
|
This time a year ago, biotech execs were in the worst mood we’ve seen in the eight years we’ve been surveying them. IPOs were on... |
|
|
 |
|
Adam Friedman, Antares Therapeutics CEO |
|
|
|
by Reynald Castaneda
|
Antares Therapeutics will be collaborating with Novartis to find unique small molecule candidates for multiple “undruggable” cancer targets, with the biotech receiving $105 million upfront... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
📊 Verastem’s KRAS G12D plans: Verastem’s Tuesday releaseon its KRAS G12D drug didn’t include much efficacy data — the company said that key update... | |
|
|
|
|
|
|
|
|
by Lei Lei Wu
|
Ollin Biosciences announced a $330 million Series B to fund pivotal studies around what it hopes can be a more potent competitor to Genentech’s eye... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
Building on a pact from 2022, Eli Lilly has signed a new discovery collaboration with Abbisko Therapeutics that could see it pay the Chinese biotech... | |
|
|
|
|
|
